BMO lifts Protagonist Therapeutics price target to $190
BMO Capital raised its Protagonist Therapeutics price target to $190.00 per share from $178.00 and maintained an Outperform rating, per Benzinga/TradingView.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.